Because of considerable upfront costs, CAR-T(°) treatments are in the process of being reviewed by a number of countries to determine whether they represent value for money. Many countries have determined that the early evidence indicates a benefit, but there is uncertainty due...
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
BRUSSELS, Jan 30th, 2020. The Health Ministers of Belgium, the Netherlands, Luxembourg, Austria and Ireland have strong reservations in relation to the plans of Novartis and AveXis to let chance decide which seriously ill children will receive medication before it reaches the...
On 25 and 26 November 2019, the Beneluxa Initiative held its Steering Committee meeting and General Assembly in The Hague and considered the progress made in the collaboration and the future work agenda. Technical experts have been collaborating to produce HTA reports; a common...